ArticleFuture oncology (London, England)2025

SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma.

Thomas B Powles et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.